-
FDA Accepts sNDAs to Review Traditional Approval for AMONDYS 45 and VYONDYS 53
Today, Sarepta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the
-
FDA accepts Sarepta’s application to convert AMONDYS 45 and VYONDYS 53 from accelerated to full approval
Proposed text: CureDuchenne was an early funder of Sarepta Therapeutics, and we are pleased to








